Nasal administration of transforming growth factor-beta1 induces dendritic cells and inhibits protracted-relapsing experimental allergic encephalomyelitis
- PMID: 10408719
- DOI: 10.1177/135245859900500308
Nasal administration of transforming growth factor-beta1 induces dendritic cells and inhibits protracted-relapsing experimental allergic encephalomyelitis
Abstract
Cytokines have a crucial role in initiation and perturbation of EAE that represents an animal model of multiple sclerosis (MS). Administration of transforming growth factor-beta1 (TGF-beta1) to EAE mice improves clinical EAE and prevents relapses by unknown mechanisms. Administering low doses of TGF-beta1 nasally, we confirmed that TGF-beta1 inhibited development and relapse of protracted-relapsing EAE (PR-EAE) in DA rats. Infiltration of CD4+ T-cells and macrophages within the central nervous system was clearly reduced, while proliferation and IFN-gamma secretion of mononuclear cells (MNC) was augmented in TGF-beta1-treated EAE rats compared to PBS-treated control EAE rats. TGF-beta1 administered nasally also increased nitric oxide production and CD4+ T cell apoptosis. TGF-beta1 treated rats showed augmented proliferation of dendritic cells (DC) compared to MNC. These data imply that low doses of TGF-beta1 given by the nasal route prevent PR-EAE and upregulate DC functions that may be involved for disease prevention.
Similar articles
-
TGF-beta1 inhibits protracted-relapsing experimental autoimmune encephalomyelitis by activating dendritic cells.J Autoimmun. 2000 May;14(3):213-20. doi: 10.1006/jaut.2000.0364. J Autoimmun. 2000. PMID: 10756083
-
Mechanisms of recovery from experimental allergic encephalomyelitis induced with myelin basic protein peptide 68-86 in Lewis rats: a role for dendritic cells in inducing apoptosis of CD4+ T cells.J Neuroimmunol. 1999 Jun 1;97(1-2):25-36. doi: 10.1016/s0165-5728(99)00041-7. J Neuroimmunol. 1999. PMID: 10408975
-
The complexicity of cytokine treatment in ongoing EAE induced with MBP peptide 68-86 in Lewis rats.Clin Immunol. 2000 Apr;95(1 Pt 1):70-8. doi: 10.1006/clim.2000.4833. Clin Immunol. 2000. PMID: 10794434
-
Rat models as tool to develop new immunotherapies.Immunol Rev. 2001 Dec;184:117-28. doi: 10.1034/j.1600-065x.2001.1840111.x. Immunol Rev. 2001. PMID: 11918681 Review.
-
TGF-beta as a promising option in the treatment of multiple sclerosis.Neuropharmacology. 2009 May-Jun;56(6-7):929-36. doi: 10.1016/j.neuropharm.2009.02.007. Epub 2009 Mar 11. Neuropharmacology. 2009. PMID: 19285095 Review.
Cited by
-
The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis.Acta Neuropathol. 2019 May;137(5):757-783. doi: 10.1007/s00401-019-01980-7. Epub 2019 Mar 7. Acta Neuropathol. 2019. PMID: 30847559 Free PMC article. Review.
-
The impact of vitamin D3 intake on inflammatory markers in multiple sclerosis patients and their first-degree relatives.PLoS One. 2020 Apr 6;15(4):e0231145. doi: 10.1371/journal.pone.0231145. eCollection 2020. PLoS One. 2020. PMID: 32251441 Free PMC article.
-
Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis.Mediators Inflamm. 2015;2015:513295. doi: 10.1155/2015/513295. Epub 2015 Jan 29. Mediators Inflamm. 2015. PMID: 25705093 Free PMC article. Review.
-
The neuroprotective functions of transforming growth factor beta proteins.Int J Mol Sci. 2012;13(7):8219-8258. doi: 10.3390/ijms13078219. Epub 2012 Jul 3. Int J Mol Sci. 2012. PMID: 22942700 Free PMC article.
-
The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease.J Exp Med. 2007 Mar 19;204(3):571-82. doi: 10.1084/jem.20061931. Epub 2007 Mar 5. J Exp Med. 2007. PMID: 17339406 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
